Primary Care Clinics in Silsbee, TX Accepting Medicare
6 Primary Care Clinics found. Showing 1 - 6
 Aceso Urgent Care -silsbee Tx, Llc Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 205 E Avenue J, Silsbee, TX 77656 Phone: 409-351-4158 |
Gulf Coast Health Center Inc Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 755 N 4th St, Silsbee, TX 77656 Phone: 409-386-1222 Fax: 409-983-4933 |
Head To Toe Family Healthcare Clinic/Center - Primary Care Medicare: Medicare Enrolled Practice Location: 735 N 5th St, Silsbee, TX 77656 Phone: 409-385-6500 Fax: 409-385-6505 |
Riceland Medical Center (and Clinics) Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 1350 Highway 327 E, Silsbee, TX 77656 Phone: 409-385-7744 |
Silsbee Family Medicine, Pa Clinic/Center - Primary Care Medicare: Medicare Enrolled Practice Location: 280 Highway 418 E, Silsbee, TX 77656 Phone: 409-386-1200 Fax: 409-386-1219 |
J. M. Patil, M. D., P. A. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 603 Highway 418 W, Ste #1, Silsbee, TX 77656 Phone: 409-385-9497 Fax: 409-385-9464 |
News Archive
New discovery opens door to development of new treatments that stop progression of Parkinson's disease
A research led by the Research Institute Vall d'Hebron (VHIR), in which the University of Valencia participated, has shown that pathological forms of the α-synuclein protein present in deceased patients with Parkinson's disease are able to initiate and spread in mice and primates the neurodegenerative process that typifies this disease.
FDA extends action date for Pfizer's tofacitinib NDA review
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).
FDA approves Lupin's Norgestimate and Ethinyl Estradiol Tablets
Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA).
Hearing aids may hold potential to cut older adults' hospital or ER visits
Hearing aids cost thousands of dollars, and insurance almost never covers them. But they may hold the potential to cut older adults' visits to the hospital or emergency room, according to a new study.
› Verified 1 days ago